These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 32665537

  • 21. Tumor-associated macrophages promote epithelial-mesenchymal transition and the cancer stem cell properties in triple-negative breast cancer through CCL2/AKT/β-catenin signaling.
    Chen X, Yang M, Yin J, Li P, Zeng S, Zheng G, He Z, Liu H, Wang Q, Zhang F, Chen D.
    Cell Commun Signal; 2022 Jun 17; 20(1):92. PubMed ID: 35715860
    [Abstract] [Full Text] [Related]

  • 22. β-Catenin is required for the tumorigenic behavior of triple-negative breast cancer cells.
    Xu J, Prosperi JR, Choudhury N, Olopade OI, Goss KH.
    PLoS One; 2015 Jun 17; 10(2):e0117097. PubMed ID: 25658419
    [Abstract] [Full Text] [Related]

  • 23. Long non-coding RNA CCAT2 promotes oncogenesis in triple-negative breast cancer by regulating stemness of cancer cells.
    Xu Z, Liu C, Zhao Q, Lü J, Ding X, Luo A, He J, Wang G, Li Y, Cai Z, Wang Z, Liu J, Liu S, Li W, Yu Z.
    Pharmacol Res; 2020 Feb 17; 152():104628. PubMed ID: 31904506
    [Abstract] [Full Text] [Related]

  • 24. LINC01572 promotes triple-negative breast cancer progression through EIF4A3-mediated β-catenin mRNA nuclear exportation.
    Zheng B, Zhou B, Ye D, Wang Y, Zheng W, Wang X, Liu D, Qian F, Zhou X, Yan T, Li Y, Fang L.
    Environ Toxicol; 2024 May 17; 39(5):3026-3039. PubMed ID: 38317508
    [Abstract] [Full Text] [Related]

  • 25. Combined inhibition of EGFR and c-ABL suppresses the growth of triple-negative breast cancer growth through inhibition of HOTAIR.
    Wang YL, Overstreet AM, Chen MS, Wang J, Zhao HJ, Ho PC, Smith M, Wang SC.
    Oncotarget; 2015 May 10; 6(13):11150-61. PubMed ID: 25883211
    [Abstract] [Full Text] [Related]

  • 26. Lnc RNA H19 is associated with poor prognosis in breast cancer patients and promotes cancer stemness.
    Shima H, Kida K, Adachi S, Yamada A, Sugae S, Narui K, Miyagi Y, Nishi M, Ryo A, Murata S, Taniguchi H, Ichikawa Y, Ishikawa T, Endo I.
    Breast Cancer Res Treat; 2018 Aug 10; 170(3):507-516. PubMed ID: 29693231
    [Abstract] [Full Text] [Related]

  • 27. Microenvironmental Regulation of Long Noncoding RNA LINC01133 Promotes Cancer Stem Cell-Like Phenotypic Traits in Triple-Negative Breast Cancers.
    Tu Z, Schmöllerl J, Cuiffo BG, Karnoub AE.
    Stem Cells; 2019 Oct 10; 37(10):1281-1292. PubMed ID: 31283068
    [Abstract] [Full Text] [Related]

  • 28. HOXD3 Plays a Critical Role in Breast Cancer Stemness and Drug Resistance.
    Zhang Y, Zhang Q, Cao Z, Huang Y, Cheng S, Pang D.
    Cell Physiol Biochem; 2018 Oct 10; 46(4):1737-1747. PubMed ID: 29698974
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Destabilization of β-catenin and RAS by targeting the Wnt/β-catenin pathway as a potential treatment for triple-negative breast cancer.
    Ryu WJ, Lee JD, Park JC, Cha PH, Cho YH, Kim JY, Sohn JH, Paik S, Choi KY.
    Exp Mol Med; 2020 May 10; 52(5):832-842. PubMed ID: 32457491
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. In vivo β-catenin attenuation by the integrin α5-targeting nano-delivery strategy suppresses triple negative breast cancer stemness and metastasis.
    Li Y, Xiao Y, Lin HP, Reichel D, Bae Y, Lee EY, Jiang Y, Huang X, Yang C, Wang Z.
    Biomaterials; 2019 Jan 10; 188():160-172. PubMed ID: 30352320
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Tocilizumab potentiates cisplatin cytotoxicity and targets cancer stem cells in triple-negative breast cancer.
    Alraouji NN, Al-Mohanna FH, Ghebeh H, Arafah M, Almeer R, Al-Tweigeri T, Aboussekhra A.
    Mol Carcinog; 2020 Sep 10; 59(9):1041-1051. PubMed ID: 32537818
    [Abstract] [Full Text] [Related]

  • 35. Targeting LRP8 inhibits breast cancer stem cells in triple-negative breast cancer.
    Lin CC, Lo MC, Moody R, Jiang H, Harouaka R, Stevers N, Tinsley S, Gasparyan M, Wicha M, Sun D.
    Cancer Lett; 2018 Dec 01; 438():165-173. PubMed ID: 30227220
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Differential activation of Wnt-β-catenin pathway in triple negative breast cancer increases MMP7 in a PTEN dependent manner.
    Dey N, Young B, Abramovitz M, Bouzyk M, Barwick B, De P, Leyland-Jones B.
    PLoS One; 2013 Dec 01; 8(10):e77425. PubMed ID: 24143235
    [Abstract] [Full Text] [Related]

  • 38. Wnt-beta-catenin pathway signals metastasis-associated tumor cell phenotypes in triple negative breast cancers.
    De P, Carlson JH, Wu H, Marcus A, Leyland-Jones B, Dey N.
    Oncotarget; 2016 Jul 12; 7(28):43124-43149. PubMed ID: 27281609
    [Abstract] [Full Text] [Related]

  • 39. NOTCH4 maintains quiescent mesenchymal-like breast cancer stem cells via transcriptionally activating SLUG and GAS1 in triple-negative breast cancer.
    Zhou L, Wang D, Sheng D, Xu J, Chen W, Qin Y, Du R, Yang X, He X, Xie N, Liu S, Zhang L.
    Theranostics; 2020 Jul 12; 10(5):2405-2421. PubMed ID: 32104513
    [Abstract] [Full Text] [Related]

  • 40. MiR-125b regulates the proliferation and metastasis of triple negative breast cancer cells via the Wnt/β-catenin pathway and EMT.
    Nie J, Jiang HC, Zhou YC, Jiang B, He WJ, Wang YF, Dong J.
    Biosci Biotechnol Biochem; 2019 Jun 12; 83(6):1062-1071. PubMed ID: 30950326
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.